[Retracted] Receptor tyrosine kinases in carcinogenesis (Review)
Affiliations: Nanjing University of Chinese Medicine, Information Institute, Nanjing, Jiangsu 221009, P.R. China, Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China
- Published online on: September 4, 2020 https://doi.org/10.3892/ol.2020.12062
- Article Number: 195
Copyright : © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Lett 12: [Related article:] 3679-3682, 2016; DOI: 10.3892/ol.2016.5200
Following the publication of this article, an interested reader drew to our attention that the flow of the text, and the wording of numerous passages of text within the article, bore striking and unexpected similarities to the wording employed in a PhD thesis by Salam Khan at the Karolinska Institutet in Stockholm in 2015 entitled “Targeting Chronic Lymphocytic Leukemia cells using Anti-ROR1 Monoclonal Antibodies and Small Molecule Inhibitors”.
After having conducted an internal investigation, the Editor of Oncology Letters has determined beyond all reasonable doubt that the review submitted to the Journal shared an unacceptable level of identity with the PhD thesis by Salam Khan. The authors were contacted about these apparent similarities between their review and the thesis, and they agree to this retraction. The Editor of Oncology Letters deeply regrets that this article was not intercepted by our own checks for plagiarism prior to the publication of the review, and sincerely apologizes to the author of the PhD thesis and the readership for the inconvenience caused. We also thank the reader for bringing this matter to our attention.